TABLE 1.
Expression of RAK antigens in women with breast cancer
| Tissue or cells | No. of samples tested/no. (%) positive for RAK antigen |
|---|---|
| Breast cancer | 125/119a 6b (95.2, 4.8) |
| NAT | 70/8a 9b (11.4, 12.9) |
| Normal breastc | 40/3a 1b (7.5, 2.5) |
| Breast with fibrocystic disease | 35/2a 1b (5.7, 2.8) |
| Breast reductiond | 10/1b (10) |
| Breast milk | 10/0 (0) |
| Skin | 10/0 (0) |
| Placenta | 2/0 (0) |
| MCF 7, SiHae | A,a B,a Ca |
a
Moderate to very high expression of RAK p120, p42, and p25.
b
Low expression of all three antigens or expression of only two antigens.
c
The majority of “normal” tissues were obtained from the cancer-affected breast.
d
Breast reduction cases are theoretically normal cases. In the United States, one of every eight women will develop breast cancer during her lifetime; therefore, some premalignant changes may occur.
e
MCF 7 and SiHa are breast and cervical cell lines, respectively, grown under laboratory conditions for 1 year (A) or 2 to 3 weeks (B) or freshly supplied by ATCC.